132.87
price down icon0.24%   -0.32
after-market After Hours: 132.87
loading
Biogen Inc stock is traded at $132.87, with a volume of 633.33K. It is down -0.24% in the last 24 hours and up +0.78% over the past month. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$133.19
Open:
$133.49
24h Volume:
633.33K
Relative Volume:
0.39
Market Cap:
$19.85B
Revenue:
$9.82B
Net Income/Loss:
$1.48B
P/E Ratio:
13.12
EPS:
10.13
Net Cash Flow:
$2.30B
1W Performance:
+4.69%
1M Performance:
+0.78%
6M Performance:
-12.71%
1Y Performance:
-40.84%
1-Day Range:
Value
$132.21
$134.42
1-Week Range:
Value
$123.90
$134.75
52-Week Range:
Value
$110.03
$238.00

Biogen Inc Stock (BIIB) Company Profile

Name
Name
Biogen Inc
Name
Phone
(781) 464-2000
Name
Address
225 BINNEY STREET, CAMBRIDGE, MA
Name
Employee
7,605
Name
Twitter
@biogen
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
BIIB's Discussions on Twitter

Compare BIIB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
BIIB
Biogen Inc
132.87 19.85B 9.82B 1.48B 2.30B 10.13
Drug Manufacturers - General icon
LLY
Lilly Eli Co
780.67 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
156.01 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.17 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
189.28 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
121.90 234.21B 53.22B 12.86B 14.85B 6.39

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-28-25 Downgrade HSBC Securities Buy → Hold
Apr-04-25 Downgrade Argus Buy → Hold
Feb-11-25 Initiated Bernstein Mkt Perform
Jan-02-25 Downgrade Piper Sandler Overweight → Neutral
Dec-20-24 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-16-24 Downgrade Stifel Buy → Hold
Dec-10-24 Resumed BofA Securities Neutral
Dec-09-24 Downgrade Jefferies Buy → Hold
Nov-18-24 Downgrade Needham Buy → Hold
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-14-24 Initiated Citigroup Neutral
Oct-31-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-10-24 Resumed Raymond James Mkt Perform
Feb-14-24 Reiterated Needham Buy
Feb-14-24 Downgrade Wells Fargo Overweight → Equal Weight
Jan-24-24 Downgrade UBS Buy → Neutral
Dec-20-23 Resumed Cantor Fitzgerald Overweight
Dec-07-23 Upgrade Raymond James Mkt Perform → Outperform
Sep-06-23 Initiated HSBC Securities Buy
Jul-27-23 Initiated Scotiabank Sector Outperform
Jul-24-23 Reiterated UBS Buy
May-01-23 Upgrade Guggenheim Neutral → Buy
Apr-17-23 Upgrade Piper Sandler Neutral → Overweight
Oct-26-22 Upgrade Goldman Neutral → Buy
Oct-13-22 Upgrade Stifel Hold → Buy
Oct-07-22 Upgrade Argus Hold → Buy
Sep-28-22 Upgrade BMO Capital Markets Market Perform → Outperform
Sep-28-22 Upgrade Mizuho Neutral → Buy
Sep-28-22 Upgrade Robert W. Baird Neutral → Outperform
Apr-18-22 Upgrade Wells Fargo Equal Weight → Overweight
Mar-08-22 Downgrade Stifel Buy → Hold
Mar-03-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-04-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-04-22 Reiterated Barclays Equal Weight
Feb-04-22 Reiterated BofA Securities Neutral
Feb-04-22 Reiterated Cowen Outperform
Feb-04-22 Reiterated Morgan Stanley Overweight
Feb-04-22 Reiterated Needham Buy
Feb-04-22 Reiterated Oppenheimer Outperform
Feb-04-22 Reiterated RBC Capital Mkts Sector Perform
Feb-04-22 Reiterated Robert W. Baird Neutral
Feb-04-22 Reiterated Wedbush Neutral
Feb-04-22 Reiterated Wells Fargo Equal Weight
Feb-04-22 Reiterated Wolfe Research Peer Perform
Jan-13-22 Downgrade Guggenheim Buy → Neutral
Jan-12-22 Downgrade Piper Sandler Overweight → Neutral
Dec-10-21 Resumed Raymond James Mkt Perform
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Initiated BMO Capital Markets Outperform
Sep-23-21 Initiated Needham Buy
Jun-18-21 Upgrade Piper Sandler Neutral → Overweight
Jun-14-21 Reiterated Truist Buy
Jun-11-21 Upgrade Bernstein Mkt Perform → Outperform
Jun-10-21 Upgrade UBS Neutral → Buy
Jun-08-21 Upgrade Atlantic Equities Underweight → Neutral
Jun-08-21 Reiterated Barclays Equal Weight
Jun-08-21 Upgrade Citigroup Sell → Neutral
Jun-08-21 Reiterated H.C. Wainwright Buy
Jun-08-21 Reiterated Jefferies Buy
Jun-08-21 Reiterated Morgan Stanley Overweight
Jun-08-21 Reiterated RBC Capital Mkts Sector Perform
Jun-08-21 Upgrade Robert W. Baird Underperform → Neutral
Jun-08-21 Reiterated Stifel Buy
Jun-08-21 Upgrade William Blair Mkt Perform → Outperform
Jun-07-21 Upgrade BofA Securities Underperform → Neutral
Jun-07-21 Upgrade Cowen Market Perform → Outperform
Jun-07-21 Upgrade Raymond James Underperform → Mkt Perform
Feb-05-21 Downgrade DZ Bank Buy → Hold
Jan-29-21 Upgrade Stifel Hold → Buy
Nov-10-20 Upgrade DZ Bank Hold → Buy
Nov-09-20 Downgrade Atlantic Equities Neutral → Underweight
Nov-09-20 Downgrade BofA Securities Neutral → Underperform
Nov-09-20 Downgrade Cowen Outperform → Market Perform
Nov-09-20 Reiterated H.C. Wainwright Buy
Nov-04-20 Upgrade BofA Securities Underperform → Neutral
Nov-04-20 Upgrade Jefferies Hold → Buy
Nov-04-20 Upgrade Wells Fargo Equal Weight → Overweight
Oct-28-20 Initiated UBS Neutral
Jul-27-20 Upgrade Morgan Stanley Underweight → Overweight
Jun-22-20 Downgrade Barclays Overweight → Equal Weight
Jun-22-20 Reiterated RBC Capital Mkts Sector Perform
Jun-09-20 Downgrade Bernstein Outperform → Mkt Perform
Apr-23-20 Downgrade Citigroup Neutral → Sell
Apr-23-20 Downgrade Raymond James Mkt Perform → Underperform
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Jan-27-20 Upgrade Canaccord Genuity Hold → Buy
Dec-13-19 Upgrade Credit Suisse Underperform → Neutral
Dec-02-19 Downgrade Robert W. Baird Neutral → Underperform
View All

Biogen Inc Stock (BIIB) Latest News

pulisher
Jun 18, 2025

Missouri Trust & Investment Co Has $866,000 Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla - insights.citeline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Grimes & Company Inc. Purchases 33,721 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Fifth Third Bancorp Has $751,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen bids to extend use of Skyclarys to younger patients - pharmaphorum

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Dips on Its Part in BRAVE Study - Baystreet.ca

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxol - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia | BIIB Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen initiates phase 3 trial of omaveloxolone for children with FA - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Biogen

Jun 18, 2025
pulisher
Jun 18, 2025

How the Neuroprotection Therapeutics Market Will Evolve by 2032 - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Harbor Capital Advisors Inc. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With ‘Fit for Growth’ Plan - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa KirinResearchAndMarkets.com - Bluefield Daily Telegraph

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen patents new HTT splicing modulators - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Eyes Contingent Value in Sage Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bill Nye joins fireside chat supporting Biogen’s Cannes Lion-winning work - Medical Marketing and Media

Jun 17, 2025
pulisher
Jun 16, 2025

NorthCrest Asset Manangement LLC Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire

Jun 16, 2025
pulisher
Jun 15, 2025

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

Biogen's (BIIB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Pallas Capital Advisors LLC Purchases 7,694 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals

Jun 13, 2025
pulisher
Jun 13, 2025

Neuroregeneration Therapy Market Know the Scope and Trends | - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

Data at EULAR back Biogen, UCB's first-in-class lupus drug - pharmaphorum

Jun 13, 2025
pulisher
Jun 12, 2025

Biogen Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandle - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandler Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 ResultsBiogen (NASDAQ:BIIB) - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Earns Neutral Rating from Wedbush - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen: positive Phase 3 data in lupus - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Receives Hold Rating from Needham & Company LLC - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Demystifying Biogen: Insights From 11 Analyst Reviews - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus D - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News - GuruFocus

Jun 12, 2025

Biogen Inc Stock (BIIB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general SNY
$48.30
price down icon 2.05%
$111.75
price up icon 0.22%
drug_manufacturers_general PFE
$25.38
price up icon 0.24%
$298.24
price up icon 0.47%
drug_manufacturers_general MRK
$80.93
price down icon 1.77%
drug_manufacturers_general NVS
$121.90
price down icon 1.54%
Cap:     |  Volume (24h):